Stock rebound uncertain for U.S. biotechs as risks multiply for investors

U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.